This is a prospective study designed to evaluate the efficacy and safety of vigabatrin as first-
choice monotherapy in infants with West syndrome. One hundred sixteen patients with …

A multicentre, long-term, open-label, add-on study of vigabatrin was undertaken in 23
pretreated children with infantile spasms. After 3 months of vigabatrin therapy 11 of the 23 …

The clinical and electroencephalographic (EEG) response to combined therapy with
vigabatrin and topiramate was evaluated in five patients ages 7 to 15 months affected by …

Original article Vigabatrin as a First-Line Drug in West s. schmi~ Syndrome: Clinical and
Electroencephalographic Outcome Page 1 Original article Gabriele Wohlrab Vigabatrin as a …

Purpose: Vigabatrin (VGB) has been shown to be an effective drug in the treatment of
infantile spasms (West syndrome) in predominantly retrospective and open but also in …

Objective Hormonal therapy and vigabatrin are now accepted as the first-line or standard
therapies for West syndrome (WS). However, the superiority of these drugs in terms of …

The interpretation of the results of the use of vigabatrin (VGB) in generalized seizures and
epilepsies in children has been difficult. Most studies have assessed patients on the basis of …

The combination of axial spasms in clusters, hypsarrhythmia, and psychomotor delay
beginning in the first year of life defines West syndrome. Adrenocorticotrophic hormone …

Purpose: Vigabatrin (VGB) is a new‐generation anticonvulsant used in the treatment of
partial seizures and West syndrome. Side effects of VGB treatment in adults and children are …

Background and purpose: Long‐term follow‐up of children with idiopathic West syndrome
(WS) treated with adrenocorticotropic hormone (ACTH) or vigabatrin. Methods: Records of …